As record levels of money pour into gene therapy research, biotechs are under pressure to answer questions on safety, delivery and pipelines. Gene therapy is once again at the forefront of biomedical research, catalyzed by advances in safer delivery of genes to cells.

INCLUDED IN THIS TRENDLINE

• A rare biotech IPO raises $175M for Prime Medicine and its gene editing technology
• With $2.8M gene therapy, Bluebird sets new bar for US drug pricing
• ‘We have to find a way’: FDA seeks solutions to aid bespoke gene therapy